Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Metab Eng ; 15: 167-73, 2013 Jan.
Article in English | MEDLINE | ID: mdl-23164580

ABSTRACT

The rapK gene required for biosynthesis of the DHCHC starter acid that initiates rapamycin biosynthesis was deleted from strain BIOT-3410, a derivative of Streptomyces rapamycinicus which had been subjected to classical strain and process development and capable of robust rapamycin production at titres up to 250mg/L. The resulting strain BIOT-4010 could no longer produce rapamycin, but when supplied exogenously with DHCHC produced rapamycin at titres equivalent to its parent strain. This strain enabled mutasynthetic access to new rapalogs that could not readily be isolated from lower titre strains when fed DHCHC analogs. Mutasynthesis of some rapalogs resulted predominantly in compounds lacking late post polyketide synthase biosynthetic modifications. To enhance the relative production of fully elaborated rapalogs, genes encoding late-acting biosynthetic pathway enzymes which failed to act efficiently on the novel compounds were expressed ectopically to give strain BIOT-4110. Strains BIOT-4010 and BIOT-4110 represent valuable tools for natural product lead optimization using biosynthetic medicinal chemistry and for the production of rapalogs for pre-clinical and early stage clinical trials.


Subject(s)
Genetic Enhancement/methods , Mutagenesis, Site-Directed/methods , Recombination, Genetic/genetics , Sirolimus/metabolism , Streptomyces/physiology , Sirolimus/isolation & purification , Species Specificity , Streptomyces/classification
2.
Proc Natl Acad Sci U S A ; 108(12): 4776-81, 2011 Mar 22.
Article in English | MEDLINE | ID: mdl-21383123

ABSTRACT

The macrocyclic polyketides FK506, FK520, and rapamycin are potent immunosuppressants that prevent T-cell proliferation through initial binding to the immunophilin FKBP12. Analogs of these molecules are of considerable interest as therapeutics in both metastatic and inflammatory disease. For these polyketides the starter unit for chain assembly is (4R,5R)-4,5-dihydroxycyclohex-1-enecarboxylic acid derived from the shikimate pathway. We show here that the first committed step in its formation is hydrolysis of chorismate to form (4R,5R)-4,5-dihydroxycyclohexa-1,5-dienecarboxylic acid. This chorismatase activity is encoded by fkbO in the FK506 and FK520 biosynthetic gene clusters, and by rapK in the rapamycin gene cluster of Streptomyces hygroscopicus. Purified recombinant FkbO (from FK520) efficiently catalyzed the chorismatase reaction in vitro, as judged by HPLC-MS and NMR analysis. Complementation using fkbO from either the FK506 or the FK520 gene cluster of a strain of S. hygroscopicus specifically deleted in rapK (BIOT-4010) restored rapamycin production, as did supplementation with (4R,5R)-4,5-dihydroxycyclohexa-1,5-dienecarboxylic acid. Although BIOT-4010 produced no rapamycin, it did produce low levels of BC325, a rapamycin analog containing a 3-hydroxybenzoate starter unit. This led us to identify the rapK homolog hyg5 as encoding a chorismatase/3-hydroxybenzoate synthase. Similar enzymes in other bacteria include the product of the bra8 gene from the pathway to the terpenoid natural product brasilicardin. Expression of either hyg5 or bra8 in BIOT-4010 led to increased levels of BC325. Also, purified Hyg5 catalyzed the predicted conversion of chorismate into 3-hydroxybenzoate. FkbO, RapK, Hyg5, and Bra8 are thus founder members of a previously unrecognized family of enzymes acting on chorismate.


Subject(s)
Bacterial Proteins , Chorismic Acid/metabolism , Genes, Bacterial/physiology , Immunosuppressive Agents/metabolism , Multigene Family/physiology , Sirolimus/metabolism , Streptomyces , Tacrolimus/analogs & derivatives , Tacrolimus/metabolism , Bacterial Proteins/biosynthesis , Bacterial Proteins/chemistry , Bacterial Proteins/genetics , Chorismic Acid/chemistry , Immunosuppressive Agents/chemistry , Sirolimus/chemistry , Streptomyces/enzymology , Streptomyces/genetics , Tacrolimus/chemistry
3.
J Med Chem ; 51(18): 5494-7, 2008 Sep 25.
Article in English | MEDLINE | ID: mdl-18800759

ABSTRACT

A biosynthetic medicinal chemistry approach was applied to the optimization of the natural product Hsp90 inhibitor macbecin. By genetic engineering, mutants have been created to produce novel macbecin analogues including a nonquinone compound (5) that has significantly improved binding affinity to Hsp90 (Kd 3 nM vs 240 nM for macbecin) and reduced toxicity (MTD > or = 250 mg/kg). Structural flexibility may contribute to the preorganization of 5 to exist in solution in the Hsp90-bound conformation.


Subject(s)
Benzoquinones/pharmacology , Biological Products/pharmacology , Genetic Engineering , HSP90 Heat-Shock Proteins/antagonists & inhibitors , Lactams, Macrocyclic/pharmacology , Benzoquinones/chemistry , Benzoquinones/metabolism , Biological Products/chemistry , Biological Products/metabolism , HSP90 Heat-Shock Proteins/metabolism , Lactams, Macrocyclic/chemistry , Lactams, Macrocyclic/metabolism , Molecular Sequence Data , Molecular Structure
SELECTION OF CITATIONS
SEARCH DETAIL
...